WALL STREET INTRADAY, MONDAY

Biggest point gainers: BIIB 296.12(19.12), REGN 358.31(16.92), CMG 384.4(13.97), BLK 358.71(12.91), NILE 40.75(10.31), IBB 261.4(9.7),TQQQ 120.53(8.18), NTES 251.57(8.14), HUM 173.9(6.48), ROK 124(6.44), STZ 165.51(5.92), TMO 152.38(5.81), JAZZ 108.79(5.69), CMI129.98(5.67), UHS 125.79(5.44), BAP 161.24(5.42), AVGO 177.5(5.33), IONS 32.45(5.32), CHTR 255.33(5.1), INCY 92.63(5.06), SHW247.49(4.95), PH 125.43(4.88), GS 180.69(4.77), PANW 152.7(4.7), NOC 229.87(4.64)

Biggest point losers: TVIX 17.4(-4.8), HSNI 32.35(-3.65), GOLD 82.68(-3.21), BIS 37.69(-3.08), ALXN 126.18(-2.82), AEM 49.01(-2.67), FNV65.01(-2.38), WRK 44.35(-2), NEM 35.87(-1.93), RGLD 74.42(-1.4), PINC 28.91(-1.34), ABX 17.06(-1.22), LEXAV 43.87(-1.13), SQQQ 14.06(-1.09), SLW 22.77(-1.03), TLT 130.77(-0.97), EPAM 60.78(-0.95), AU 13.29(-0.89), LXFT 49.3(-0.85), TMH 41.83(-0.83), USLV 18(-0.8), SBGL 10.9(-0.77), UGLD 11.74(-0.71), GG 14.61(-0.7), SA 10.68(-0.68)

Gainers on news:

• Ionis Pharma (IONS +20.31%) and Biogen (BIIB) announce Spinraza meets primary endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy
• ChemoCentryx (CCXI +8.72%) announces presentations of 'positive' results from the Phase II CLEAR and CLASSIC trials of CCX168 at Kidney Week and the ACR 2016 meeting
• Versartis (VSAR +6.04%) presents safety, efficacy, and IGF-I data from somavaratan treatment in the combined Phase 2a and ongoing VISTA long-term safety study for pediatric GHD

Decliners on news:

• InfuSystem (INFU -4.7%) concludes that various prior financial statements should no longer be relied upon

Gainers on earnings:

• Amicus Therapeutics (FOLD +16.12%) misses by $0.02; updates anticipated milestones
• Horizon Pharma (HZNP +15.55%) beats by $0.08, reports revs in-line; reaffirms FY16 revs guidance
• BioCryst Pharma (BCRX +11.51%) beats by $0.10, beats on revs; updates financial guidance & provides a corporate update

Decliners on earnings:

• Concordia (CXRX -36.36%) misses by $0.33, misses on revs; suspends guidance
• Nobilis Health (HLTH -13.33%) misses by $0.10, beats on revs; reaffirms FY16 revs guidance
• Aurinia Pharma (AUPH -6.67%) misses by $0.06

Upgrades/Downgrades:

• TherapeuticsMD (TXMD +11.43%) resumed with a Buy at Guggenheim
• Celldex Therapeutics (CLDX +7.12%) Aegis Capital Initiated Coverage: BUY
• Alder BioPharma (ALDR +7.25%) Aegis Capital Initiated Coverage: BUY
• Premier (PINC -4.61%) downgraded to Underperform from Buy at BofA/Merrill

 Stocks that traded to 52 week highs: AA, ABCB, AGO, AIMC, AIR, AMBC, AMKR, AVG, AXS, BAH, BCOR, BDE, BGFV, BOH, BOOM, BSAC, BSBR, CBD, CC, CFG, CLD, CNV, CORT, CSC, CSX, CWEI, CWST, DE, DTLK, EME, FDX, FMC, FTAI, GIMO, HNRG, HRS, HSKA, IBOC, IM, IPHS, IQNT, IR, IRBT, KE, KEY, KWR, LBAI, LOPE, LSCC, LSTR, LVS, MENT, MGM, MTD, MTRN, MYRG, NAV, NILE, NOA, NRP, OEC, OFG, ORN, PF, PFMT, POWI, RF, RNR, SAIA, SEMI, SMI, SNI, STL, STLD, SWFT, SXCP, TMHC, TNC, TOWN, TTMI, TTWO, TWNK, UCTT, UNVR, VALE, VECO, VRNS, VRTV, VSH, WAFD, WBS, WIFI, WLB

Stocks that traded to 52 week lows: ALV, CBIO, CERU, CGI, CHMA, CLLS, CORE, CRME, CTG, CXRX, EGY, EPAM, ETRM, EYES, FALC, FES, GLRI, GSVC, HSNI, IMNP, INAP, KEP, LFVN, LIVN, MDRX, NAO, NDLS, NGG, NVO, NXEO, PINC, PLUG, PPP, PRXL, PULM, PZRX, QVCA, RELY, SEAC, SSH, SSW, STON, SYRX, TINY, TLOG, TNDM, VMEM, VOD, VRML